Toxicology Safety Assessment & Regulatory Submission Navigator
Verify toxicology submission readiness and navigate FDA/ICH regulatory pathways
What You Can Do
You can assess your complete toxicology data package against ICH guidelines and FDA submission standards, then receive a tailored compliance checklist based on your regulatory pathway (IND, NDA, BLA, ANDA, CTA, or IMPD). The skill identifies missing documentation, flags non-compliant safety summaries, and validates that your CTD module 2.3.7 sections meet agency expectations—helping you avoid Complete Response Letters and accelerate market entry.
Features
Input your product type and indication; receive guidance on whether IND, CTA, IMPD, NDA, BLA, or ANDA applies
Compare your toxicology package against ICH M3(R2), ICH M7, and FDA guidance documents to identify missing studies or data
Evaluate draft CTD 2.3.7.1 sections for completeness, format, and regulatory language standards
Generate a prioritized checklist of documentation, study reports, and summaries required for your specific pathway
Cross-reference your data package against age-appropriate safety pharmacology, ADME, and toxicology study requirements
Identify differences between US FDA, EMA, and PMDA requirements for simultaneous submissions
Systematically address regulatory agency feedback and re-assess compliance against original submission gaps
Example Output
Example 1: IND Submission Readiness
✓ Regulatory Pathway: IND (Investigational New Drug) — Phase 1 oncology indication
✓ Compliance Status: 8/10 sections complete
⚠ Missing Items:
- GLP-compliant 28-day repeat-dose toxicity study (rodent)
- Preliminary ADME/PK data in animal model
- Reproductive/developmental toxicity justification
Example 2: Safety Summary Draft Feedback
Your CTD 2.3.7.1 safety summary covers: ✓ Pharmacology ✓ Pharmacokinetics & metabolism ⚠ Toxicology: Missing target organ toxicity discussion ⚠ Human safety data: Not applicable (first-in-human)
Suggestion: Add organ-specific findings table and reference supporting study appendices.
Example 3: Multi-Region Submission Gaps
US FDA: Requires phototoxicity study (Type I photosensitizer suspected) EMA: Waives phototoxicity if in vitro data negative JapAN PMDA: Equivalent to FDA; phototoxicity required
Recommendation: Conduct phototoxicity study to align US/Japan requirements.
What's Included
- SKILL.md instruction file with regulatory framework and submission workflow:
- Regulatory Pathway Decision Tree: flowchart to select IND, CTA, IMPD, NDA, BLA, or ANDA
- ICH Compliance Checklist Template: itemized requirements for M3(R2), M7, safety pharmacology, and ADME
- CTD 2.3.7 Safety Summary Outline: section-by-section template with FDA/EMA language standards
- CRL Remediation Tracker: framework for systematically addressing agency feedback and re-submission planning
- Multi-Region Requirement Comparison Matrix: FDA vs. EMA vs. PMDA standards side-by-side
Who It's For
- Toxicologists preparing preclinical data packages for regulatory submission
- Regulatory Scientists and Regulatory Affairs Professionals managing IND, CTA, NDA, or BLA submissions
- Quality Assurance/Compliance leads verifying submission readiness before filing
- Preclinical Program Managers transitioning programs from R&D to regulatory
- Clinical Development teams responding to Complete Response Letters or agency requests
Best For
- IND, CTA, IMPD, NDA, BLA, and ANDA submission preparation
- Safety summary (CTD 2.3.7) drafting and validation
- Regulatory pathway selection and indication-specific compliance assessment
- Multi-region (US, EU, Japan) simultaneous submission strategy planning
- Post-CRL gap remediation and re-submission readiness verification
- Competitive benchmarking against approved therapeutics in your indication
You might also like
You can submit tool designs—drawings, specifications, or descriptions—and Claude will evaluate manufacturability constraints, identify potential failure modes using structured frameworks, and recommend cost-reduction opportunities. You'll receive a prioritized report covering structural analysis, production feasibility, material efficiency, and design trade-offs.
by kody-w
You can automate the validation of clinical trial data against protocol specifications, identify discrepancies including missing values, out-of-range results, protocol violations, and CRF inconsistencies. The skill generates audit-ready query documentation, categorizes anomalies by severity and type, resolves root causes systematically, and produces FDA inspection-ready reports that trace every data decision and corrective action for CDISC and regulatory submission.
by kody-w
You can submit raw mass spectrometry observations, instrument parameters, or sample preparation details to Claude and receive targeted diagnostic frameworks that explain anomalous results. Claude systematically generates plausible mechanistic explanations for unexpected protein abundance patterns, quantification inconsistencies, and PTM findings—then helps you design minimal, hypothesis-driven troubleshooting experiments to test them.
by kody-w
You can take unstructured monitoring visit observations and convert them into formal, audit-ready reports that categorize findings by risk level (Critical, Major, Minor), validate protocol compliance, and generate actionable follow-up items with assigned owners and resolution dates. The skill ensures your documentation meets FDA inspection standards and ICH-GCP requirements while creating clear escalation pathways for high-risk issues.
by kody-w
You can validate eCRF and paper CRF datasets against protocol-defined rules, automatically identify data discrepancies (missing fields, out-of-range values, date inconsistencies), generate structured Data Query Forms (DQFs) for site clarification, track resolution status, and create audit-ready compliance documentation that meets FDA 21 CFR Part 11 and GCP requirements. This workflow reduces manual validation time while ensuring 100% traceability and regulatory readiness for inspections.
by kody-w
Get comprehensive PCB design analysis covering power delivery networks, signal integrity, thermal management, and manufacturing constraints. Claude identifies potential issues early and provides specific, actionable optimization recommendations to reduce cost, improve reliability, and accelerate time-to-market. Suitable for designs from initial concept through production-ready layouts.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-w
This skill systematically analyzes your product designs to identify manufacturability issues early, saving costly revisions and manufacturing delays. It evaluates geometry, material selection, tolerances, assembly feasibility, and production process constraints. You get actionable feedback on cost drivers, process risks, and design optimizations before committing to production.
by kody-w